{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:19:49Z","timestamp":1760235589933,"version":"build-2065373602"},"reference-count":51,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T00:00:00Z","timestamp":1630627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Epidermal growth factor receptor\u2013tyrosine kinase inhibitors (EGFR-TKIs) are effective first-line chemotherapeutic agents for patients with advanced non-small-cell lung cancer (NSCLC) harboring drug-sensitive EGFR mutations. However, the effectiveness of EGFR-TKI rechallenge after first-line EGFR-TKI treatment is not sufficient in elderly patients (over 75 years of age) harboring drug-sensitive EGFR mutations. Therefore, we investigated the effectiveness and safety of EGFR-TKI rechallenge after first-line EGFR-TKI treatment in elderly patients with advanced NSCLC harboring drug-sensitive EGFR mutations. Materials and Methods: Between April 2008 and December 2015, we analyzed 78 elderly patients with advanced NSCLC harboring drug-sensitive EGFR mutations with first-line EGFR-TKI treatment at four Japanese institutions. We retrospectively evaluated the clinical effectiveness and safety profiles of EGFR-TKI rechallenge after first-line EGFR-TKI treatment in elderly patients with advanced NSCLC harboring drug-sensitive EGFR mutations (exon 19 deletion\/exon 21 L858R mutation). Results: Twenty-two patients in the cohort were rechallenged with EGFR-TKI. The median age was 79.5 years (range 75\u201387 years). Despite the fact that it was a retrospective analysis, even with EGFR-TKI rechallenge treatment the response rate was 23%, progression-free survival was 5.3 months, and overall survival was 14.4 months. Common adverse events included rash acneiform, paronychia, diarrhea, and anorexia. There were no treatment-related deaths. Due to the occurrence of adverse events of grade 2 or more, dose reduction was performed in 15 (68.2%) of 22 cases. Conclusions: EGFR-TKI rechallenge treatment after first-line EGFR-TKI treatment in elderly patients with advanced NSCLC harboring drug-sensitive EGFR mutations was one of the limited, safe and effective treatment options for elderly EGFR-positive lung cancer patients.<\/jats:p>","DOI":"10.3390\/medicina57090929","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T13:09:25Z","timestamp":1630933765000},"page":"929","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations"],"prefix":"10.3390","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6823-4231","authenticated-orcid":false,"given":"Yutaka","family":"Yamada","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Ibaraki Prefectural Central Hospital, Kasama 309-1793, Ibaraki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3097-4255","authenticated-orcid":false,"given":"Hisao","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama University Hospital, Hidaka 350-1298, Saitama, Japan"},{"name":"Division of Respiratory Medicine, Gunma Prefectural Cancer Center, Ota 373-8550, Gunma, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohide","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Division of Thoracic Oncology, Tochigi Cancer Center, Utsunomiya 320-0834, Tochigi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8710-1960","authenticated-orcid":false,"given":"Hiroyuki","family":"Minemura","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Fukushima Medical University, Fukushima 960-1295, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenya","family":"Kanazawa","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Fukushima Medical University, Fukushima 960-1295, Japan"},{"name":"Clinical Oncology Center, Fukushima Medical University Hospital, Fukushima 960-1295, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kasai","sequence":"additional","affiliation":[{"name":"Division of Thoracic Oncology, Tochigi Cancer Center, Utsunomiya 320-0834, Tochigi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Minato","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Gunma Prefectural Cancer Center, Ota 373-8550, Gunma, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5548-7686","authenticated-orcid":false,"given":"Kyoichi","family":"Kaira","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama University Hospital, Hidaka 350-1298, Saitama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Kaburagi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Ibaraki Prefectural Central Hospital, Kasama 309-1793, Ibaraki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3322\/caac.21349","article-title":"Cancer treatment and survivorship statistics, 2016","volume":"66","author":"Miller","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1200\/JCO.2009.25.4052","article-title":"Chemotherapy and survival benefit in elderly patients with advanced non-small cell lung cancer","volume":"28","author":"Davidoff","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"5570","DOI":"10.1200\/JCO.2007.12.5435","article-title":"Lung cancer in elderly patients: An analysis of the surveillance, epidemiology, and end results database","volume":"25","author":"Owonikoko","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomized phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1093\/annonc\/mdv276","article-title":"Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)","volume":"26","author":"Zhou","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(14)71173-8","article-title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung ad-enocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trials","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1097\/JTO.0b013e318260de8b","article-title":"First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study","volume":"7","author":"Maemondo","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Fujita, S., Katakami, N., Masago, K., Yoshioka, H., Tomii, K., Kaneda, T., and Mio, T. (2012). Customized chemotherapy based on epidermal growth factor receptor mutation status for elderly patients with advanced non-small-cell lung cancer: A phase II trial. BMC Cancer, 12.","DOI":"10.1186\/1471-2407-12-185"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s12032-012-0450-2","article-title":"Clinical outcomes in elderly patients administered gefitinib as first-line treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer: Retrospective analysis in a Nagano Lung Cancer Research Group study","volume":"30","author":"Tateishi","year":"2013","journal-title":"Med. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.lungcan.2013.07.003","article-title":"A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC)","volume":"82","author":"Goto","year":"2013","journal-title":"Lung Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00280-014-2548-z","article-title":"First-line gefitinib therapy for elderly patients with non-small cell lung cancer harboring EGFR mutation: Central Japan Lung Study Group 0901","volume":"74","author":"Takahashi","year":"2014","journal-title":"Cancer Chemother. Pharm."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00280-015-2841-5","article-title":"First-line gefitinib treatment in elderly patients (aged>\/=75 years) with non-small cell lung cancer harboring EGFR mutations","volume":"76","author":"Kuwako","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): An open-label, randomised phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients with Metastatic Lung Adenocarcinoma with EGFR Mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.lungcan.2009.06.025","article-title":"Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy","volume":"68","author":"Tomizawa","year":"2010","journal-title":"Lung Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00280-018-3596-6","article-title":"Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations","volume":"82","author":"Imai","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/JTO.0b013e31812f3c1a","article-title":"International Association for the Study of Lung Cancer International Staging Committee. The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours","volume":"2","author":"Goldstraw","year":"2007","journal-title":"J. Thorac. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"7276","DOI":"10.1158\/0008-5472.CAN-05-0331","article-title":"Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp","volume":"65","author":"Nagai","year":"2005","journal-title":"Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2353\/jmoldx.2006.050104","article-title":"A Rapid, Sensitive Assay to Detect EGFR Mutation in Small Biopsy Specimens from Lung Cancer","volume":"8","author":"Yatabe","year":"2006","journal-title":"J. Mol. Diagn."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S1470-2045(12)70087-6","article-title":"Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b\/3 randomised trial","volume":"13","author":"Miller","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.lungcan.2016.12.002","article-title":"Predictive factors for EGFR -tyrosine kinase inhibitor retreatment in patients with EGFR -mutated non-small-cell lung cancer \u2013 A multicenter retrospective SEQUENCE study","volume":"104","author":"Chang","year":"2017","journal-title":"Lung Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-016-2917-6","article-title":"Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors","volume":"16","author":"Chen","year":"2016","journal-title":"BMC Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.cllc.2014.07.008","article-title":"Rationale and Study Design of the IRENE-Trial (NVALT-16): A Phase II Trial to Evaluate Iressa Rechallenge in Advanced NSCLC Patients With an Activating EGFR Mutation Who Responded to an EGFR-TKI Used As First-Line or Previous Treatment","volume":"16","author":"Kuiper","year":"2015","journal-title":"Clin. Lung Cancer"},{"key":"ref_28","first-page":"270","article-title":"Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI","volume":"11","author":"Xia","year":"2014","journal-title":"Cancer Biol. Med."},{"key":"ref_29","first-page":"400","article-title":"Re-administration after the failure of gefitinib or erlotinib in patients with advanced non-small cell lung cancer","volume":"5","author":"Song","year":"2013","journal-title":"J. Thorac. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/annonc\/mds214","article-title":"Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)","volume":"24","author":"Inoue","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e201250","DOI":"10.1001\/jamaoncol.2020.1250","article-title":"Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer A Multicenter Phase 2 Trial","volume":"6","author":"Miyamoto","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1200\/JCO.2006.06.1044","article-title":"Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904)","volume":"24","author":"Kudoh","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.resinv.2014.10.002","article-title":"Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: Sensitivity and resistance","volume":"52","author":"Takeuchi","year":"2014","journal-title":"Respir. Investig."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinumpemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Ko, R., Kenmotsu, H., Serizawa, M., Koh, Y., Wakuda, K., Ono, A., and Takahashi, T. (2016). Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2902-0"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Pereira, I., Gaspar, C., Pina, M., Azevedo, I., and Rodrigues, A. (2020). Real-World T790M Mutation Frequency and Impact of Rebiopsy in Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer. Cureus, 12.","DOI":"10.7759\/cureus.12128"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/1759-7714.13857","article-title":"Clinical impact of rebiopsy among patients with epidermal growth factor receptor-mutant lung adenocarcinoma in a real-world clinical setting","volume":"12","author":"Nam","year":"2021","journal-title":"Thorac. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/1759-7714.13822","article-title":"Higher osimertinib introduction rate achieved by multiple repeated rebiopsy after acquired resistance to first\/second generation EGFR-TKIs","volume":"12","author":"Ninomaru","year":"2021","journal-title":"Thorac. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Mountzios, G., Koumarianou, A., Bokas, A., Mavroudis, D., Samantas, E., Fergadis, E., Linardou, H., Katsaounis, P., Athanasiadis, E., and Karamouzis, M. (2021). A Real-World, Observational, Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations upon Progression on or after First-Line Therapy with a First- or Second-Generation EGFR Tyrosine Kinase Inhibitor in EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: The \u2018LUNGFUL\u2019 Study. Cancers, 13.","DOI":"10.20944\/preprints202104.0732.v1"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1002\/cam4.3948","article-title":"Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer","volume":"10","author":"Zhang","year":"2021","journal-title":"Cancer Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/S1470-2045(15)00121-7","article-title":"Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutationpositive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): A phase 3 randomised trial","volume":"16","author":"Soria","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1200\/JCO.2014.55.8627","article-title":"Randomized phase III trial comparing weekly docetaxel plus cisplatin versus docetaxel monotherapy every 3 weeks in elderly patients with advanced non-small-cell lung cancer: The intergroup trial JCOG0803\/WJOG4307L","volume":"33","author":"Abe","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(11)60780-0","article-title":"Carboplatinand weekly paclitaxel doublet chemotherapy compared with mono-therapy in elderly patients with advanced non-small-cell lung cancer: IFCT- 0501 randomised, phase 3 trial","volume":"378","author":"Quoix","year":"2011","journal-title":"Lancet"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.21873\/anticanres.13544","article-title":"Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib\/Erlotinib?","volume":"39","author":"Tamiya","year":"2019","journal-title":"Anticancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"785","DOI":"10.7314\/APJCP.2016.17.2.785","article-title":"Low-dose Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibition of EGFR Mutation-positive Lung Cancer: Therapeutic Benefits and Associations Between Dosage, Efficacy and Body Surface Area","volume":"17","author":"Hirano","year":"2016","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/1759-7714.13047","article-title":"Clinical analysis ofEGFR-positive non-small cell lung cancer patients treated with first-line afatinib: A Nagano Lung Cancer Research Group","volume":"10","author":"Sonehara","year":"2019","journal-title":"Thorac. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","article-title":"Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Nakagawa","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S2213-2600(19)30267-X","article-title":"Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: A multicentre, open-label, phase 1 study","volume":"8","author":"Tan","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/S1470-2045(19)30504-2","article-title":"Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study","volume":"20","author":"Ahn","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/1759-7714.13302","article-title":"Abivertinib in patients with T790M-positive advanced NSCLC and its subsequent treatment with osimertinib","volume":"11","author":"Wang","year":"2020","journal-title":"Thorac. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.jtho.2020.09.001","article-title":"Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial","volume":"15","author":"Yang","year":"2020","journal-title":"J. Thorac. Oncol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/9\/929\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:55:50Z","timestamp":1760165750000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/9\/929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,3]]},"references-count":51,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["medicina57090929"],"URL":"https:\/\/doi.org\/10.3390\/medicina57090929","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2021,9,3]]}}}